Drug Profile
Ozagrel
Alternative Names: Cataclot; Domenan; KCT-0809; OKY 046; OXY-046 HCl; Vega; XanbonLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Kissei Pharmaceutical; Ono Pharmaceutical
- Developer Kissei Pharmaceutical; Teika Pharmaceutical
- Class Antiasthmatics; Antihistamines; Antithrombotics; Methacrylates; Small molecules
- Mechanism of Action Thromboxane A2 receptor antagonists; Thromboxane A2 synthase inhibitors; Thromboxane synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Asthma; Cerebral vasospasm; Diabetic nephropathies; Intracranial thrombosis
- Discontinued Cerebral infarction; Cough; Dry eyes; Glomerulonephritis; Hypertension in pregnancy; Myocardial infarction; Transplant rejection
Most Recent Events
- 26 May 2017 Kissei Pharmaceutical completes a phase III trial in Dry eyes (associated with Sjögren's Syndrome) in Japan (Ophthalmic) (NCT02503189)
- 24 Apr 2017 Kissei Pharmaceutical terminates a phase III extension trial for Dry eyes in Japan since the results of the Phase III clinical study conducted in Japan failed to demonstrate the expected efficacy of this drug (Opthalmic) (NCT02503163)
- 24 Apr 2017 Kissei Pharmaceutical terminates a phase III extension trial for Dry eyes in Japan since the results of the Phase III clinical study conducted in Japan failed to demonstrate the expected efficacy of this drug (Opthalmic) (NCT02503176)